2025 / 02

Next Paper
DOI: 10.24075/brsmu.2025.014
Copyright: © 2025 by the authors. Licensee: Pirogov University.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).

ORIGINAL RESEARCH

PD1 expression in immune cells within the tumor microenvironment of patients with non-small cell and small cell lung cancer

Kalinchuk AYu, Tsarenkova EA, Loos DM, Mokh AA, Rodionov EO, Miller SV, Grigoryeva ES, Tashireva LA
About authors

The Laboratory of Molecular Therapy of Cancer, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia

Correspondence should be addressed: Evgenia S. Grigoryeva
Evgenia S. Grigoryeva pereulok Kooperativnyj, 5, Tomsk, Russia; moc.liamg@se.aveyrogirg

About paper

Funding: the study was supported by the Russian Science Foundation (grant № 20-75-10033-П).

Author contribution: Kalinchuk AYu — literature search, obtaining and statistically processing the results, writing the article; Tsarenkova EA — obtaining and analyzing data; Loos DM — obtaining and analyzing data; Mokh AA — patients’ curation; Rodionov EO — patients’ curation; Miller SV — data collection; ES Grigoryeva — editing the article; Tashireva LA — study planning and supervision, analysis, and interpretation of results, writing the article.

Compliance with ethical standards: The study was approved by the Ethics Committee of the Tomsk National Research Medical Center Oncology Research Institute (protocol № 7, 25 August 2020; protocol № 18, 25 August 2023), conducted in accordance with federal laws of the Russian Federation and the 1964 Helsinki Declaration with all subsequent additions and amendments regulating scientific research on biomaterial obtained from humans. All participants signed informed voluntary consent to participate in the study.

Received: 2025-03-04 Accepted: 2025-03-17 Published online: 2025-03-24
|
  1. Hynds RE, Frese KK, Pearce DR, Grönroos E, Dive C, Swanton C. Progress towards non-small-cell lung cancer models that represent clinical evolutionary trajectories. Open Biol. 2021; 11 (1): 200247. DOI: 10.1098/rsob.200247.
  2. Thommen DS, Schreiner J, Müller P, Herzig P, Roller A, Belousov A, et al. Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors. Cancer immunology research. 2015; 3: 1344–55. DOI: 10.1158/2326-6066.CIR-15-0097.
  3. Enfield KSS, Colliver E, Lee C, Magness A, Moore DA, Sivakumar M, et al. Spatial Architecture of Myeloid and T Cells Orchestrates Immune Evasion and Clinical Outcome in Lung Cancer. Cancer Discov. 2024; 14 (6): 1018–47. DOI: 10.1158/2159-8290.CD-23-1380.
  4. Lin Z, Gu J, Cui X, Huang L, Li S, Feng J et al. Deciphering Microenvironment of NSCLC based on CD8+ TIL Density and PD-1/PD-L1 Expression. J Cancer. 2019; 10 (1): 211–22. DOI:10.7150/jca.26444.
  5. Wu J, Wang Y, Huang Z, Wu J, Sun H, Zhou R, et al. Tumor microenvironment assessment-based signatures for predicting response to immunotherapy in non-small cell lung cancer. iScience. 2024; 27 (12): 111340. DOI: 10.1016/j.isci.2024.111340.
  6. Dan A, Aricak O, Rounis K, Montero-Fernandez MA, Guijarro R, Ekman S. et al. PD-1 expression in tumor infiltrating lymphocytes as a prognostic marker in early-stage non-small cell lung cancer. Front Oncol. 2024; 14: 1414900. DOI: 10.3389/fonc.2024.1414900.
  7. Sun C, Zhang L, Zhang W, Liu Y, Chen B, Zhao S, et al. Expression of PD-1 and PD-L1 on Tumor-Infiltrating Lymphocytes Predicts Prognosis in Patients with Small-Cell Lung Cancer. OncoTargets and Therapy. 2020; 13: 6475–83. Available from: https://doi.org/10.2147/OTT.S252031.
  8. Mazzaschi G, Madeddu D, Falco A, Bocchialini G, Goldoni M, Sogni F et al. Low PD-1 Expression in Cytotoxic CD8+ TumorInfiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value. Clin Cancer Res. 2018; 24 (2): 407–19. DOI: 10.1158/1078-0432.CCR-17-2156.
  9. Kansy BA, Concha-Benavente F, Srivastava RM, Jie HB, Shayan G, Lei Y, et al. PD-1 Status in CD8(+) T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer. Cancer Res. 2017; 77: 6353–64. DOI: 10.1158/0008-5472.CAN-16-3167.
  10. Chen L, Cao MF, Xiao JF, Ma QH, Zhang H, Cai RL, et al. Stromal PD-1+ tumor-associated macrophages predict poor prognosis in lung adenocarcinoma. Hum Pathol. 2020; 97: 68–79. DOI: 10.1016/j.humpath.2019.12.007.
  11. Tao H, Mimura Y, Aoe K, Kobayashi S, Yamamoto H, Matsuda E, et al. Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells. Lung Cancer. 2012; 75 (1): 95–101. DOI: 10.1016/j.lungcan.2011.06.002.